Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
Acacia Pharma Group plc
Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
Cambridge, UK and Indianapolis, US – 20 January 2021: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, announces that application has been made to Euronext Brussels for the admission of the 30,000 Ordinary Shares of £0.02 each (the “New Ordinary Shares”) to trading on Euronext Brussels ("Admission") to satisfy the exercise of options granted under the Company’s Enterprise Management Incentive Share Option Plan. The New Ordinary Shares will rank pari passu in all respects with the Company's existing Ordinary Shares in issue.
Following issue of the New Ordinary Shares, the Company's total issued share capital consists of 89,627,951 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares, the total number of voting rights in the Company is 89,627,951.
Contacts
| Acacia Pharma Group plc Mike Bolinder, CEO Gary Gemignani, CFO / | International Media Mark Swallow, Frazer Hall, David Dible Citigate Dewe Rogerson 1 |
| US Investors LifeSci Advisors Irina Koffler | Media in Belgium and the Netherlands Chris Van Raemdonck 1 |
